2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an <scp>ELN‐DAVID</scp> expert panel
Lenalidomide promotes the development of <i>TP53</i>-mutated therapy-related myeloid neoplasms
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Targeted therapy with the mutant <i>IDH2</i> inhibitor enasidenib for high-risk <i>IDH2</i>-mutant myelodysplastic syndrome
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Prognostic impact of <i>NPM1</i> and <i>FLT3</i> mutations in patients with AML in first remission treated with oral azacitidine
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS
Ong, F, Kadia, TM, Short, NJ, Yilmaz, M, Alvarado, Y, Sasaki, K, Pierce, S, Garcia-Manero, G, DiNardo, C, Borthakur, G, Konopleva, M, Daver, N, Kantarjian, HM, Ravandi-Kashani, F . AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). Clinical Lymphom
— 2022cited by 0position: selected
Ravandi-Kashani, F , Wei, A, Döhner, H, Sayar, H, Montesinos, P, Dombret, H, Selleslag, D, Porkka, K, Jang, JH, Skikne, B, Beach, CL, Tian, Y(, Roboz, G . AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC). Clinical
— 2022cited by 0position: selected
Ravandi F . EXABS-149-AML Is All Oral Therapy of AML a Reality for the Future?. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S58, 2022. e-Pub 2022. PMID: 36164230.
— 2022cited by 0position: selected
Ravandi F . Are We Witnessing a Paradigm Shift in the Treatment of Acute Myeloid Leukemia?. Cancer J 28(1):1, 2022. e-Pub 2022. PMID: 35072367.
— 2022cited by 0position: selected
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations
Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i>-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology